Cardiology | Healthcare | Medical | Pulmonary
One Shot to Silence Heart Disease: How CRISPR Gene Editing Is Making Daily Cholesterol Pills Obsolete
A single infusion of CRISPR gene editing therapy has cut LDL cholesterol by up to 87 percent and triglycerides by up to 84 percent in landmark clinical trials. With Phase 2 studies now enrolling, three competing programs from CRISPR Therapeutics, Verve Therapeutics, and Scribe Therapeutics are racing to replace daily statin pills with a permanent genetic fix for cardiovascular disease.
